Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
Sponsor: Novartis Pharmaceuticals
A observational or N/A phase clinical study on Heart Failure With Reduced Ejection Fraction (HF-rEF), this trial is ongoing. The trial is conducted by Novartis Pharmaceuticals and has accumulated 17 data snapshots since 2026. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
No Longer Available
-
Sep 2024 — Sep 2025 [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Mar 2021 — Jul 2024 [monthly]
No Longer Available
Status: Available → No Longer Available
-
Jan 2021 — Mar 2021 [monthly]
Available
▶ Show 12 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Available
-
Dec 2018 — Feb 2020 [monthly]
Available
-
Nov 2018 — Dec 2018 [monthly]
Available
-
Sep 2018 — Nov 2018 [monthly]
Available
-
Jul 2018 — Sep 2018 [monthly]
Available
-
Jun 2018 — Jul 2018 [monthly]
Available
-
Apr 2018 — Jun 2018 [monthly]
Available
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Available NA
-
Oct 2017 — Feb 2018 [monthly]
Available NA
-
Sep 2017 — Oct 2017 [monthly]
Available NA
-
Feb 2017 — Sep 2017 [monthly]
Available NA
-
Jan 2017 — Feb 2017 [monthly]
Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abu Dhabi, United Arab Emirates , Ahlen, Germany , Alexandroupoli, Greece , Amiens, France , Amilly, France , Angers, France , Antibes, France , Aressy, France , Athens, Greece , Augsburg, Germany and 200 more locations